Quantifying the Burden of Type 2 (T2) Inflammation in Asthma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorIcahn School of Medicine at Mount Sinai
About this trial
This study is designed to support the assessment of Type 2 (T2) biomarkers in asthma in primary care and community specialty practices. To assess T2 biomarkers, individuals will be required to complete a breath test for fractional exhaled nitric oxide (FeNO) and consent to a review of their medical records. Asthma often goes undetected in primary care and community settings, and through this study the researchers hope to optimize referral pathways to care.
Eligibility criteria
Qualifiers
Ability to consent and comply with protocol assessments
Pre-existing diagnosis of asthma and has started treatment
Disqualifiers
Participant deemed medically ineligible per the opinion of the investigator
History of respiratory/lung disease other than asthma (e.g., COPD, emphysema, chronic bronchitis, tuberculosis, cystic fibrosis, lung cancer, recurrent pneumonia or other chronic lung disease)
Participants who meet criteria for GINA 5, severe asthma (ICS + additional controllers)
Current Enrollment in an asthma intervention trial that could affect asthma outcomes clinically and T2 biomarkers
Trial design
Treatments tested in this trial
- FeNO Breath Test
Treatment groups
200 Participants
are divided into 1 treatment groupSponsors and collaborators
Icahn School of Medicine at Mount Sinai
Lead sponsor
Sanofi
Collaborator
Source ClinicalTrials.gov